期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他克莫司治疗的监测方法 被引量：9

下载PDF
导出
摘要 他克莫司是一种新的大环内酯类抗生素 ,具有极强的免疫抑制作用 ,但其毒副作用也不可忽视。它的药物动力学受多种因素影响 ,显示广泛的变异性 ,毒副作用在大多数病人中呈现剂量相关性 ,因此对他克莫司进行血药浓度监测很有必要。本文就他克莫司治疗中与药物监测有关的问题如 :样本的选择 ;样品的纯化及预处理 ;血样贮存的稳定性 ;血药浓度监测方法 ;推荐治疗剂量、血药浓度范围。
作者 徐新军 刘皋林 张正行
机构地区 中国药科大学药学院 第二军医大学长征医院临床药理研究室
出处 《国外医药（抗生素分册）》 CAS 2001年第5期222-227,共6页 World Notes on Antibiotics
关键词 他克莫司 治疗药物监测 稳定性 酶联免疫分析 微粒子酶免疫分析 血药浓度
分类号 R979.5 [医药卫生—药品] R969.1 [医药卫生—药理学]
  • 相关文献

参考文献29

  • 1[1]Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomycies.1. Fermentation, isolation, and physico-chemical and biological characteristics. [J]. J Antibiot, 1987,40:1249
  • 2[2]Ireland RE, Liu LB, Roper TU, et al. Total synthesis of FK506. [J]. Tetrahedron, 1997, 53 (39): 13257
  • 3[3]Caroline M, Spencer, Karen L, et al. Tacrolimus:an update of its pharmacology and clinical efficacy in the management of organ transplantation. [J]. Drugs, 1997, 54(6): 925
  • 4[4]Dasgupta A,Timmerman TG. Therapeutic monitoring of tacrolimus using liquid chromatography. [J]. J Liq Chromatogr, 1995,18(20) :4029
  • 5[5]Venkataramanan R, Swaminathan A, Prasad T,et al. Clinal pharmacokinetics of tacrolimus. [J]. Clin Pharmacokinet.1995,29(6) :404
  • 6[6]Lampen A, Christians U, Guengerich FP, et al.Metabolism of the immunosuppressant FK in the small intestine: cytochrome P450, drug interactions and interindividual variability. [J]. Drug Metab Dispos, 1995,23 (12):1315
  • 7[7]Winkler M ,Christians U,Stoll K, et al. Comparison of different assays for the quantitation of FK506 levels in blood or plasma. [J]. Ther Drug Monit ,1994,16(3):281
  • 8[8]Warty V, Zuckermans, Venkataramanan R, et al.Tacrolimus analysis:A comparison of different methods and matrices. [J]. Ther Drug Monit, 1995,17 (2) : 159
  • 9[9]Winkerler M, Christians U, Gonschior AK. Evauation of the new Pro-Trac tacrolimus, monoclonal whole blood ELISA for monitoring tacrolimus levels in patients after kidney , heart and liver transplant. [J]. Ther Drug Monit, 1995,17: 430
  • 10[10]Freeman DJ,Stawecki M,Howson B. Stability of FK506in whole blood samples. [J]. Ther Drug Monit, 1995,17(3): 266

同被引文献47

  • 1夏东亚,刘龙,郭涛,蒋苓,段万玲.他克莫司在肾移植患者的体内药动学[J].中国药学杂志,2004,39(10):778-780. 被引量：3
  • 2穆安娜.FK506在肝移植中的应用[J].激光杂志,2005,26(2):12-12. 被引量：1
  • 3申济奎,李辰.FK506对大鼠穿透性角膜移植排斥反应的免疫抑制作用[J].眼科研究,1996,14(4):217-219. 被引量：3
  • 4Alak AM. Measurement of tacrolimus (FK506) and its metabolites: a review of assay development and application in theraputic drug monitoring and pharmacokinetic studies. Ther Drug Monit, 1997,19:338-351.
  • 5Zhang Q, Simpson J , Aboleneen HI. A specific method for the measurement of FK506 in human whole blood by liquid chromatography/tandem mass spectrometry. Ther Drug Monit, 1997, 19:470-476.
  • 6Iwasaki K. Metabolism of tacrolimus ( FK506 ) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet, 2007, 22 : 328-335.
  • 7Cogill JL, Taylor PJ, Westley IS, et al. Evaluation of the tacromlimus Ⅱ micropaticle enzyme immunoassay ( MEIA Ⅱ ) in liver and renal transplant recipients. Clin Chem, 1998, 44: 1942-1946.
  • 8van Hooff JP, Boots JM, van Duijnhoven EM, et al. Dosing and management guidelines for tacrolimus in renal transplant patients. Transplant Proc, 1999,31 (7A) :54S-57S.
  • 9National Committee for Clinical laboratory Standards. EP6-A Evalution of the linearity of quantitative measurenment procedures : a statistical approach; Approved guideline. Pennsylvania: Wayne, 2003.
  • 10National Committee for Clinical laboratory Standards. EP17-A Protocols for determination of limits of detection and limits of quantitation: Approved guideline-second edition. Pennsylvania: Wayne, 2004.

引证文献9

二级引证文献37

国外医药（抗生素分册）
2001年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部